← All trials
NCT05576077
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 30, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Jun 30, 2024
- First posted
- Oct 12, 2022
- Last posted
- Oct 13, 2022
- Enrollment
- 30
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Turnstone Biologics, Inc.Lead sponsor
- Turnstone Biologics, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.